ArticleACS synthetic biology2018
A Modular Receptor Platform To Expand the Sensing Repertoire of Bacteria.
Article in ACS synthetic biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 75 citations in OpenAlex.
- CF2H: a cell-free two-hybrid platform for rapid protein binder screening.Nature communications · 2026Article
- Programming Next-Generation Synthetic Biosensors by Genetic Circuit Design.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Engineering Allosteric Transcription Factor-Based Biosensors: Advances and Prospects for Modern Food Contaminant Monitoring.Foods (Basel, Switzerland) · 2026Review
- A Screening Assay for Bile Acid-Transforming Microorganisms Using Engineered Bacterial Biosensors.Biosensors · 2025Article
- Innovative applications and research advances of bacterial biosensors in medicine.Frontiers in microbiology · 2025Review
- Genetically engineered bacteria as inflammatory bowel disease therapeutics.Engineering microbiology · 2024Review
- A molecular toolkit for heterologous protein secretion across Bacteroides species.Nature communications · 2024Article
- Microbial biosensors for diagnostics, surveillance and epidemiology: Today's achievements and tomorrow's prospects.Microbial biotechnology · 2024Review
- Mutation of the peptide-regulated transcription factor ComR for amidated peptide specificity and heterologous function inMicrobiology spectrum · 2024Article
- LanTERN: A Fluorescent Sensor That Specifically Responds to Lanthanides.ACS synthetic biology · 2024Article
- Discovery of a high-performance phage-derived promoter/repressor system for probiotic lactobacillus engineering.Microbial cell factories · 2024Article
- Accelerating Genetic Sensor Development, Scale-up, and Deployment Using Synthetic Biology.Biodesign research · 2024Article
- A molecular toolkit for heterologous protein secretion acrossbioRxiv : the preprint server for biology · 2023Article
- Rational design of small-molecule responsive protein switches.Protein science : a publication of the Protein Society · 2023Review
- Advances in Synthetic-Biology-Based Whole-Cell Biosensors: Principles, Genetic Modules, and Applications in Food Safety.International journal of molecular sciences · 2023Review
- Characterization of Eight Bacterial Biosensors for Microbial Diagnostic and Therapeutic Applications.ACS synthetic biology · 2022Article
- Strategies for Improving Small-Molecule Biosensors in Bacteria.Biosensors · 2022Review
- Achieving spatially precise diagnosis and therapy in the mammalian gut using synthetic microbial gene circuits.Frontiers in bioengineering and biotechnology · 2022Review
- Programming living sensors for environment, health and biomanufacturing.Microbial biotechnology · 2021Article
- Redesign of ultrasensitive and robust RecA gene circuit to sense DNA damage.Microbial biotechnology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Engineered bacteria promise to revolutionize diagnostics and therapeutics, yet many applications are precluded by the limited number of detectable signals. Here we present a general framework to engineer synthetic receptors enabling bacterial cells to respond to novel ligands. These receptors are activated via ligand-induced dimerization of a single-domain antibody fused to monomeric DNA-binding domains (split-DBDs). Using E. coli as a model system, we engineer both transmembrane and cytosolic receptors using a VHH for ligand detection and demonstrate the scalability of our platform by using the DBDs of two different transcriptional regulators. We provide a method to optimize receptor behavior by finely tuning protein expression levels and optimizing interdomain linker regions. Finally, we show that these receptors can be connected to downstream synthetic gene circuits for further signal processing. The general nature of the split-DBD principle and the versatility of antibody-based detection should support the deployment of these receptors into various hosts to detect ligands for which no receptor is found in nature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.